文献速递细菌感染、耐药与抗菌药物

幽门螺杆菌抗菌药物耐药患者间及患者内遗传变异的前瞻性多中心临床研究

Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori.
PubMed 文献 · Clin Microbiol Infect · 2017-06-29

该研究在奥地利全境前瞻性纳入2004例未接受治疗的胃镜检查患者,分别从胃窦和胃体取材,用组织病理学和实时PCR检测幽门螺杆菌对克拉霉素和喹诺酮类的耐药。结果显示患者间及患者内耐药遗传变异常见,强调多部位取样和能识别混合感染的方法对获得可靠耐药数据是必要的。

要点

  • 幽门螺杆菌感染在同一患者不同解剖部位可呈不均一性,混合感染常见。
  • 单部位取样可能低估耐药率,需多部位取材并结合可识别混合感染的微生物学方法。
  • 患者层面合并检测结果后,克拉霉素耐药率为21%(98/465),喹诺酮类为13%(50/383)。

核心结论

  • 幽门螺杆菌不同菌株造成的解剖学不均一感染常见。
  • 前瞻性临床研究设计、多部位取样及可检测混合感染的微生物学方法,是获得代表性人群可靠耐药数据的必要条件。

研究设计与样本

  • 前瞻性、多中心临床研究,纳入奥地利全境未接受治疗的胃镜检查患者n=2004。
  • 胃窦和胃体分别采集活检样本,行组织病理学和实时PCR检测克拉霉素与喹诺酮类基因型耐药。
  • ClinicalTrials.gov标识符:NCT02925091。

主要发现

  • 组织病理学检出幽门螺杆菌感染514/2004(26%),实时PCR确认465/514(90%)。
  • 胃窦与胃体PCR结果不一致者27/514(5%),提示感染不均一。
  • 胃窦和胃体克拉霉素耐药率分别为17%(77/448)和19%(84/455),喹诺酮类耐药率分别为12%(37/310)和10%(32/334)。
  • 患者层面合并检测结果后,克拉霉素耐药率为21%(98/465),喹诺酮类耐药率为13%(50/383)。
  • 同时检出敏感和耐药幽门螺杆菌者65/465(14%)。

关键数值与推荐

  • 克拉霉素耐药:胃窦17%(77/448)、胃体19%(84/455)、患者层面21%(98/465)。
  • 喹诺酮类耐药:胃窦12%(37/310)、胃体10%(32/334)、患者层面13%(50/383)。
  • 胃窦与胃体PCR结果不一致:27/514(5%)。
  • 敏感与耐药菌混合感染:65/465(14%)。

临床怎么用

  • 对幽门螺杆菌耐药评估应采用多部位活检以提高检出混合感染与耐药的可靠性。
  • 解读单部位耐药检测结果时需考虑解剖学不均一感染可能造成的低估。
  • 选择耐药检测方法时应采用能识别混合感染的微生物学方法。

局限性

  • 原文摘要未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We report on a large prospective, multicentre clinical investigation on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. METHODS: Therapy-naive patients (n = 2004) who had undergone routine diagnostic gastroscopy were prospectively included from all geographic regions of Austria. Gastric biopsy samples were collected separately from antrum and corpus. Samples were analysed by histopathology and real-time PCR for genotypic resistance to clarithromycin and quinolones. Clinical and demographic information was analysed in relation to resistance patterns. RESULTS: H. pylori infection was detected in 514 (26%) of 2004 patients by histopathology and confirmed in 465 (90%) of 514 patients by real-time PCR. PCR results were discordant for antrum and corpus in 27 (5%) of 514 patients, indicating inhomogeneous infections. Clarithromycin resistance rates were 17% (77/448) and 19% (84/455), and quinolone resistance rates were 12% (37/310) and 10% (32/334) in antrum and corpus samples, respectively. Combination of test results per patient yielded resistance rates of 21% (98/465) and 13% (50/383) for clarithromycin and quinolones, respectively. Overall, infection with both sensitive and resistant H. pylori was detected in 65 (14%) of 465 patients. CONCLUSIONS: Anatomically inhomogeneous infection with different, multiple H. pylori strains is common. Prospective clinical study design, collection of samples from multiple sites and microbiologic methods that allow the detection of coinfections are mandatory for collection of reliable data on antimicrobial resistance patterns in representative patient populations. (ClinicalTrials.gov identifier: NCT02925091).

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Bilgilier C, Stadlmann A, Makristathis A, et al. Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. Clin Microbiol Infect. 2017. PMID: 28669844. doi:10.1016/j.cmi.2017.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。